Last reviewed · How we verify
AMPEROZIDE — Competitive Intelligence Brief
phase 2
amperozide
5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
AMPEROZIDE (AMPEROZIDE). Amperozide works by blocking an enzyme called fatty-acid amide hydrolase 1, which breaks down fatty acid amides in the brain.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AMPEROZIDE TARGET | AMPEROZIDE | phase 2 | amperozide | 5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (amperozide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AMPEROZIDE CI watch — RSS
- AMPEROZIDE CI watch — Atom
- AMPEROZIDE CI watch — JSON
- AMPEROZIDE alone — RSS
- Whole amperozide class — RSS
Cite this brief
Drug Landscape (2026). AMPEROZIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/amperozide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing